Company intelligence / Profile preview

ATPCO

Seattle, Washington, United Statesatpco.net ↗

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

Aptevo has two clinical-stage bispecific antibody programs. Mipletamig, a CD123 x CD3 bispecific with orphan status for AML, is in a Phase 1b/Phase 2 trial combined with venetoclax + azacitidine for frontline AML. ALG.APV-527, a conditional agonist of the immune co-stimulatory receptor 4–1BB and tumor antigen 5T4, co-developed with Alligator Bioscience, is in Phase 1 trials targeting multiple solid tumors. Three additional preclinical candidates are advancing toward IND.

Therapeutic areas: Oncology
Modalities: Bispecific monoclonal antibodyMonoclonal antibodyProtein (via ADAPTIR platform)
Industry: Biotech

Partnerships

Alligator Bioscience AB – co-development of ALG.APV–527.

Beyond the preview

Go deeper on ATPCO.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATPCO.

Explore the full profile